Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology

Amgen
ImmunoGen

Sep 17 2009
Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology

Companies: Amgen
Immunogen

Announcement date: Sep 17 2009

Deal value, US$m: 35.0 : sum of upfront and milestone payments

Related contracts:
Collaborative R&D and licensing agreement for TAP prodrug technology for Xenomouse antigens
Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology
Licensing agreement for maytansinoid Targeted Antibody Payload (TAP) technology

Details

Announcement date: Sep 17 2009
Bigpharma
Bigbiotech
Pharmaceutical
Biotech
Oncology
Oncology » Solid tumors

Therapy areas:
Technology types:
Antibodies » Monoclonal antibodies » Human mAb
Discovery tools

Deal components:
Licensing

Stages of development:
Discovery

Geographic focus:
Worldwide

Financials

Deal value, US$m: 35.0 : sum of upfront and milestone payments
Upfront, US$m: 1.0 : upfront payment
Milestones, US$m: 32.0 : sum of additional milestone payment
1.0 : Investigational New Drug (IND) application submitted for a novel anticaner compound that utilizes TAP technology
1.0 : Investigational New Drug (IND) application submitted for a second TAP compound

Royalty rates, %: n/d : royalties on the sales of any resulting products

Termsheet

Amgen has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

This license was taken under an agreement established in 2000 between Immunogen and Abgenix, Inc., which later was acquired by Amgen.

Under the terms of the license, Immunogen receives a $1 million license payment upfront.

© 2009-2021, Wildwood Ventures Ltd. All rights reserved.
Press Release

14 November 2011

ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP Compound Second Active IND Triggers
Another $1 Million Payment to ImmunoGen WALTHAM, Mass., Nov. 14, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Investigational New Drug (IND) application submitted by Amgen for a second TAP compound is now active. This event triggers a $1 million milestone payment to ImmunoGen.

Earlier this month, the IND for a different Amgen TAP compound also became active and triggered a $1 million milestone payment to ImmunoGen. Both compounds use ImmunoGen's TAP technology with Amgen antibodies to undisclosed targets and are in development by Amgen under an agreement between the companies.

Daniel Junius, President and CEO, commented, "On July 1 – the start of our current fiscal year – there were already six TAP compounds in clinical testing through our own programs and those of our partners, with the most advanced in Phase III. Since then, four more TAP compounds have advanced to having an active IND, and we expect our next wholly owned compound, IMGN853, to reach this stage by June. This progress speaks to the productivity of our technology, our product programs, and our partnerships."

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen, Inc. (IMGN) Licenses Anticancer Technology to Amgen (AMGN) (JOBS); Deal Worth up to $35 Million

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

Daniel Junius, President and Chief Executive Officer, commented, “Amgen has an established track record of success in oncology and an expanding presence in antibody-based therapeutics. Amgen’s interest in antibody-drug conjugates is good for the field, and we’re pleased they’ve chosen to move forward with ImmunoGen’s technology.”

This license was taken under an agreement established in 2000 between ImmunoGen and Abgenix, Inc., which later was acquired by Amgen. Under the terms of the license, ImmunoGen receives a $1 million license payment upfront. The Company also is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing, and marketing of any products resulting from this license.

The agreement established in September 2000 grants Amgen certain rights to test ImmunoGen’s maytansinoid TAP technology with antibodies to specific targets and to license — on agreed-upon terms — the right to use the technology with antibodies to these targets to develop products.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s TAP technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

Filing Data

Not available.

Contract

Not available.